A detailed history of Brave Asset Management Inc transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Brave Asset Management Inc holds 10,000 shares of ACHL stock, worth $8,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Holding current value
$8,200
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$0.82 - $1.57 $8,200 - $15,700
10,000 New
10,000 $12,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $33.4M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Brave Asset Management Inc Portfolio

Follow Brave Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brave Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brave Asset Management Inc with notifications on news.